Indications for allo-SCT in CML in 2018
| Chronic phase |
| Failure of first-line TKI and predicted poor response to second-line TKI |
| Failure to respond to first- and second-line TKIs |
| Presence of T315I mutation and/or failure to respond to ponatinib |
| Presence of repeated grade 4 cytopenias in response to treatment with different TKIs despite appropriate dose reduction and cytokine support |
| Advanced phase |
| TKI naïve |
| TKI naïve with suboptimal response to TKI |
| TKI resistant |
| Blast phase |
| Acquisition of second CP after TKI or chemotherapy salvage |
| Chronic phase |
| Failure of first-line TKI and predicted poor response to second-line TKI |
| Failure to respond to first- and second-line TKIs |
| Presence of T315I mutation and/or failure to respond to ponatinib |
| Presence of repeated grade 4 cytopenias in response to treatment with different TKIs despite appropriate dose reduction and cytokine support |
| Advanced phase |
| TKI naïve |
| TKI naïve with suboptimal response to TKI |
| TKI resistant |
| Blast phase |
| Acquisition of second CP after TKI or chemotherapy salvage |